Connect with us

Cannabis

GB Sciences’ Chief Science Officer Featured on the Cover of the Marijuana Business Magazine

Published

on

 

GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine. This edition (https://mjbizmagazine.com/digital-issues/2019-09-Oct/) examines the evolution of the medical marijuana market to serve the unique needs of two distinct market segments; providing: (1) disease-targeted medicines requiring federal government-approvals and (2) the burgeoning wellness market. Dr. Andrea Small-Howard, GB Sciences’ Chief Science Officer and Director, explains why GB Sciences is well-positioned to provide research-supported product formulations for both market segments.

My hope is that there will be a stratification that serves both kinds of customers-serious medical patients and wellness patients. They’re two very different but very real customer groups,” explains Dr. Small-Howard, CSO and Director of GB Sciences. “Our research-driven approach to product development allows us to better serve both of these new market segments.”

Despite the growth of adult use markets in the US, GB Sciences is one of several companies that sees the evolution of the medical marijuana industry as an exciting opportunity. Over the past five years, GB Sciences has focused on developing a rich network of research partners and associates within a dozen universities, hospitals, and product development companies in the US and internationally. Now GB Sciences is leveraging this network and their eight patent-pending product families to create science-driven products with complex formulations and novel delivery methods to better serve the therapeutic needs of both customer groups.

“We’ve always been heading towards the creation of both US FDA-approved and branded wellness products that are more complex formulations with a scientific mindset; for example, our cannabis-based formulation to treat Parkinson’s that is now in animal trials,” relates Dr. Small-Howard. “On the wellness side, we are convinced that novel delivery systems, such as oral thin films, will allow convenient and more efficacious dosing of cannabis compounds for customers who want the therapeutic benefits of these cannabis-based ingredients.”

John Poss, CEO of GB Sciences, commenting on the article, explains another significant factor in wellness product lines: “Pharmaceuticals can take a decade or more to develop, but wellness products can help patients right now. For example, someone with Parkinson’s Disease may be aided through a wellness product designed to support sleep, or someone with PTSD may be eased with a wellness product formulated to reduce anxiety. GB Sciences is committed to taking some of our products through the US FDA, but we don’t want patients to continue to suffer while waiting for those products to be approved and available. Although our current patent applications cover formulations addressing over 60 medical conditions, we have identified three or four that are destined for the US FDA route, while many others will be developed for the health and wellness markets. These wellness products do not contain THC, which opens many distribution possibilities.”

 

SOURCE GB Sciences, Inc.

Continue Reading
Advertisement
//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js (adsbygoogle = window.adsbygoogle || []).push({});
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Core One Labs’ Subsidiary, Core Isogenics Inc., Teams up with Reiziger Pty. Ltd. to Showcase High Yielding Nutritional Cultivation Technology

Published

on

Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) (“COOL” or the “Company”) announces that its wholly-owned subsidiary, Core Isogenics Inc., has begun a highly complex nutritional regimen to accelerate the growth of cannabis plants and increase flower yield and quality.

The Core Isogenics’ nursery and breeding rooms are now operational. Approximately 25% of the breeding rooms are now actively involved in a project with Reiziger® Holland to improve harvest yields. This is a significant milestone in the Company’s journey to seed-to-sale with increased profitability. The initial project focus will be a twelve-month study matching genetics to nutrients and creating feeding regimens specifically designed for maximum absorption and conversion of nutrients into cannabinoids. The Company has high expectations for this technology and the possible benefits for the CannaStrips™ brand.

The nursery facility is uniquely suited for this type of project with its ability to track the growing conditions in isolated rooms, as well as documenting the feeding schedule and soil condition in order to gather information to accurately assess the cultivation process. This documentation will allow the Company to consistently produce high quality products in every harvest.  This consistency is vital to the Company’s cultivation model where the goal is a predictable outcome in every harvest.

CEO of Core One Labs Inc., Brad Eckenweiler, stated, “The introduction of Reiziger® and their cultivation technology into our operation is a major step in the growth of Core One Labs. The ability to have Shaun Reid and his team of master Dutch breeders and growers share their decades of experience is extremely valuable and will result in accelerating the Core Isogenics nursery years ahead of what would have been a long learning curve. Most certainly our indoor growing ability will be the primary beneficiary with higher yields and stronger cannabinoid profiles.” The Company will continue to update the market on the development of this exciting project.

 

SOURCE Core One Labs Inc.

Continue Reading

Cannabis

IMCC Appoints Yaron Berger as CEO of IMC Holdings

Published

on

Photo source: deutschlandfunkkultur.de

 

IM Cannabis Corp. (the “Company” or “IMCC”) (CSE: IMCC), one of the world’s pioneering medical cannabis companies with operations across Europe, is pleased to announce the appointment of Yaron Berger as Chief Executive Officer of I.M.C. Holdings Ltd. (“IMC“), the Company’s wholly-owned operating subsidiary in IsraelOren Shuster will remain the Chief Executive Officer of IM Cannabis Corp.

Mr. Berger brings more than 10 years of experience in various senior roles both in public and private sectors, leading large-scale operations. Most recently, Mr. Berger was the Chief Executive Officer of Telepharma Ltd. (“Telepharma,” doing business as epharma), a leading wholesaler, direct marketer of prescription drugs and chain of pharmacies in Israel. At Telepharma, among other accomplishments, Mr. Berger re-branded its digital platform and transformed the customer experience. As an early entrant into the medical cannabis sector, Mr. Berger also established Greenpharma under Telepharma, a full-service distributor, patient counselling service provider and online resource for medical cannabis patients in Israel. Prior to his experience in the pharmaceutical sector, Mr. Berger served as the Chief Operating Officer of the National Police Academy and spent over 20 years in the Israeli Air Force, most recently as a Lieutenant Colonel.

Oren Shuster, Chief Executive Officer of IMCC said “Yaron is uniquely qualified to lead our Israeli operations under the new medical cannabis regulatory regime, which requires a high level of engagement and education for the country’s pharmacists on the benefits of medical cannabis. Yaron was an early mover in identifying the opportunity in medical cannabis and we are very excited to benefit from his expertise in the pharmacy channel to maintain IMC’s status as a leading medical cannabis brand in Israel.”

“I am thrilled to be joining the IMC team, who I have known as a leader in the medical cannabis market in Israel over the past ten years,” said Mr. Berger. “The IMC brand is synonymous with quality and innovation. The new medical cannabis reform in Israel presents a significant opportunity for the Company and the IMC brand to further elevate its market position as the preferred medical cannabis brand for physicians, pharmacists and patients.”

 

SOURCE IM Cannabis Corp.

Continue Reading

Cannabis

LCBO’s bottom line proves privatized alcohol sales a bad idea: OPSEU’s Thomas

Published

on

Photo source: LCBO.com

The LCBO’s latest profits show the Crown corporation’s value to the people of Ontario, OPSEU President Warren (Smokey) Thomas said Friday.

In its 2018/2019 annual report released Thursday, the LCBO is reporting earnings of $2.37 billion on total revenue of $6.39 billion.

Thomas said those profits go to the provincial government and pay for vital public services like health, education and highways.

“This is why the Ford government should rethink allowing corner stores and grocery stores to sell more alcohol,” said Thomas.  “Is saving folks a 10 minute drive in some cases worth jeopardizing their health care?”

OPSEU represents LCBO workers and Thomas says these frontline professionals deserve the credit for the corporation’s continued success.

“The reason the LCBO is the gold standard in selling alcohol responsibly is because of OPSEU members who make sure alcohol isn’t sold to minors or intoxicated people,” said Thomas.

“They also provide customer service that is second to none and they’re the ones who have made the LCBO a success story.”

As he read the LCBO report, OPSEU First Vice-President/Treasurer Eduardo (Eddy) Almeida reflected on the Ford government’s decision to take the sale of legalized cannabis away from the Crown Corporation.

“Think of what the LCBO’s profits would have been if Premier Ford hadn’t scrapped the plan of the former Liberal government?” said Almeida.   “I’ve put together a lot of budgets and I know how tough an exercise it is.”

“It still makes me shake my head that a government that claimed it had catastrophic financial problems would turn down massive amounts of revenue and go on the misguided course that the Conservatives took. Really? Wow.”

Almeida says municipalities who voted to opt out of Doug Ford’s foolish cannabis privatization plan should stand firm and demand a responsible plan.

“The LCBO continues to prove it’s the best option to keep controlled substances out of the hands of minors,” said Almeida.  “Municipalities and Ontarians in general should continue to demand a responsible plan and just say no to Doug’s. After all, a little competition wouldn’t be a bad thing would it?”

SOURCE Ontario Public Service Employees Union (OPSEU)

Continue Reading

Trending Online

Grassnews is a news publishing website which digests / hand picks the latest news about the cannabis industry, and serves them to you daily.

Contact us: pressroom@grassnews.net

© Grassnews.net 2019 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania